What to Expect After Bladder Tumor Removal

Recovery after bladder tumor removal follows a fairly predictable pattern: a few days of bloody urine and bladder discomfort, a waiting period for pathology results that determine what comes next, and then a long-term surveillance plan that can stretch for years. The procedure most people undergo is called a transurethral resection of bladder tumor, or TURBT, where a surgeon passes a scope through the urethra and shaves or cuts away the growth without any external incision. What surprises many patients is that the surgery itself is usually the straightforward part. The real complexity lies in what the pathology report reveals, what follow-up treatments are recommended, and how the monitoring schedule shapes daily life going forward.

The First Few Days After Surgery

Most people leave the hospital within a day or two of a TURBT. A catheter is typically left in place for one to several days to drain urine and allow the surgical site to begin healing. During the first 24 to 48 hours, the urine is often pink or red with visible blood clots, which can look alarming but is expected. One study tracking patients’ day-by-day recovery found that about 84% reported clear yellow urine by the third day after surgery.¹ If bright red bleeding continues past that point or intensifies, contact your surgical team.

Bladder spasms are the other major complaint in the early recovery window. These feel like sudden, intense urges to urinate, sometimes accompanied by a cramping sensation in the lower abdomen. They can be genuinely painful. Research has found that certain surgical factors influence how bad the spasms get, including the size of the catheter balloon inflated inside the bladder and the amount of blood lost during the procedure itself.² Your doctor can prescribe antispasmodic medication to take the edge off, and spasms typically fade once the catheter comes out.

Beyond the bladder-specific symptoms, expect general post-anesthesia effects: grogginess, mild nausea, and fatigue. Most people are back to light daily activities within a week, though heavy lifting and strenuous exercise are usually off-limits for two to three weeks to reduce the risk of bleeding from the resection site.

Complications Worth Knowing About

TURBT is considered a safe procedure, but it is still surgery on the inside of the bladder, and complications do happen. The most discussed risk is bladder perforation, where the resection instrument cuts through the bladder wall. In a large series of over 1,500 patients, perforation occurred in about 10% of cases.³ That number sounds high, but the vast majority of those perforations were minor. In the same study, roughly 86% required nothing more than leaving the catheter in place for a few extra days. Only a small fraction needed drainage or surgical repair.

The location of the perforation matters. Almost all are what’s called extraperitoneal, meaning the hole opens into the tissue surrounding the bladder rather than into the abdominal cavity itself. Extraperitoneal perforations generally heal on their own with catheter drainage.⁴ Intraperitoneal perforations, which break through into the abdominal cavity, are rarer and more serious, sometimes requiring open surgical repair.

Certain factors raise perforation risk. Tumors that invade deeper into the muscle layer require deeper cuts to remove, increasing the chance of going through the wall. Having had multiple previous TURBTs also matters, because repeated resections thin the bladder wall over time. Tumors on the side walls carry a specific risk: the obturator nerve runs nearby, and electrical stimulation during resection can cause an involuntary leg jerk that jolts the instrument deeper than intended.⁵ Your surgeon will often use nerve-blocking techniques to prevent this.

Other complications include urinary tract infections, prolonged bleeding that requires additional catheterization or, rarely, a return to the operating room, and temporary urinary frequency or urgency that can linger for several weeks.

What the Pathology Report Tells You

The tissue removed during surgery goes to a pathologist, and the report that comes back is arguably the most important piece of information in your entire treatment arc. It tells your medical team two critical things: the grade of the tumor (how abnormal the cells look under a microscope) and the stage (how deep the tumor has grown into the bladder wall).

Grade is divided into low and high. Low-grade tumors grow slowly and recur often but rarely become life-threatening. High-grade tumors are more aggressive and carry a meaningful risk of invading deeper or spreading. Stage determines whether the cancer is still confined to the inner lining of the bladder (non-muscle-invasive) or has reached the muscle layer underneath (muscle-invasive), which is a fundamentally different disease requiring more aggressive treatment.

There is an important limitation to staging from a TURBT specimen that many patients don’t know about. Guidelines recommend that pathologists not assign a stage higher than T2 (muscle invasion) based on TURBT tissue alone, because certain features can be misleading. Fat tissue, for example, exists not only around the outside of the bladder but also within the bladder’s inner layers. Finding tumor cells in fat does not necessarily mean the cancer has broken through the bladder wall.⁶ This distinction matters because overstaging could push someone toward more aggressive surgery than they actually need.

Why You May Need a Second Resection

One of the things that catches patients off guard is being told they need a second TURBT, typically four to six weeks after the first. This is not because the first surgery failed. It is a deliberate strategy to improve accuracy and outcomes, and guidelines strongly recommend it for most high-grade and T1 tumors.

The reason is straightforward: the first resection can miss residual disease. A meta-analysis of contemporary studies found that roughly 31% of T1 patients still had tumor present at the second resection, and about 3% were upstaged to muscle-invasive disease, which changed their treatment plan entirely.⁷ Catching that upstaging early makes a real difference. The same analysis showed that patients who had a repeat resection had better recurrence-free survival and overall survival compared to those who did not.

A single-center study reinforced this finding: nearly 46% of patients who underwent a second-look TURBT had residual tumor, and about 9% of the T1 tumors were identified as candidates for radical cystectomy based on what the second procedure revealed.⁸ In other words, the second procedure catches a substantial number of cases where the cancer is more advanced than the first surgery suggested, and that early detection allows for timely treatment escalation. Solid-appearing tumors at the initial resection were associated with a higher likelihood of residual disease at the second procedure.⁹

Intravesical Therapy After Surgery

For most patients with non-muscle-invasive bladder cancer, the TURBT is not the end of treatment. What follows is intravesical therapy, meaning medication delivered directly into the bladder through a catheter. The two main types are chemotherapy instillations and immunotherapy with BCG (bacillus Calmette-Guérin).

Many patients receive a single dose of chemotherapy, usually mitomycin C, within 24 hours of surgery. This immediate instillation is designed to kill any stray cancer cells floating in the bladder before they can implant and grow. Evidence shows that giving chemotherapy right after surgery, rather than waiting days, reduces the risk of recurrence by about 27%.¹⁰ This benefit held across different risk groups, which is why many centers now make it standard practice for anyone without a suspected perforation.

For intermediate- and high-risk tumors, the treatment that follows is usually BCG, a weakened form of the tuberculosis bacterium. BCG is instilled into the bladder weekly for six weeks, then in maintenance doses over months to years. It works by triggering the immune system to attack residual cancer cells on the bladder lining. BCG is the most effective intravesical treatment for reducing both recurrence and progression to more advanced disease, but it comes with side effects. Most patients experience flu-like symptoms, bladder irritation, and urinary frequency after each treatment. About 8% of patients have to stop treatment entirely because of these complications.¹¹ Severe reactions, while rare, can include systemic infection that requires treatment with anti-tuberculosis medications and corticosteroids.

When BCG Stops Working

BCG failure is one of the more difficult turning points in bladder cancer treatment. If the tumor returns despite adequate BCG therapy, the recommended next step for high-risk patients is radical cystectomy, which means removing the entire bladder.¹² That is a major operation with permanent consequences for urinary function and quality of life, and many patients are either medically unfit for it or unwilling to undergo it.

For those patients, several bladder-sparing alternatives exist, though none match the definitive cure rates of cystectomy. Options include different chemotherapy drugs instilled into the bladder (gemcitabine, docetaxel), combination approaches using heat with chemotherapy, and newer immunotherapy agents.¹³ One combination gaining traction is sequential gemcitabine and docetaxel. In a study of patients who had failed BCG, this regimen achieved a one-year progression-free survival rate of 85%, with two-year overall survival at 94%. Side effects occurred in about a third of patients, but only two out of 35 participants had to stop treatment because of them.¹⁴

Life After Bladder Removal

When the bladder does need to come out, the surgery creates a new pathway for urine. The three main options are an ileal conduit (urine drains continuously into an external bag through a small opening in the abdomen), an orthotopic neobladder (a new bladder fashioned from intestinal tissue and connected to the urethra, allowing relatively normal urination), and a ureterocutaneostomy (the ureters are brought directly to the skin surface). Each option involves trade-offs in convenience, body image, and function.

Quality-of-life research comparing these approaches in older patients found meaningful differences. The neobladder group reported higher emotional function scores, while the ureterocutaneostomy group reported more fatigue than the other groups.¹⁵ A neobladder can offer the closest experience to natural urination, but it requires significant rehabilitation and the willingness to learn a new voiding technique, which may involve sitting to urinate and manually timing voiding rather than relying on the normal urge sensation.

Caregivers are significantly affected as well. A review of the literature found that caring for someone with a urinary diversion after cystectomy carries substantial psychological burden. Major concerns among caregivers included their own mental health, the need for ongoing medical assistance, and a lack of peer support from others in similar situations.¹⁶ This is an area where asking your care team about support groups and respite resources early can make a real difference for everyone involved.

The Surveillance Schedule

Bladder cancer has one of the highest recurrence rates of any solid tumor, which is why follow-up is intensive and long-lasting. After a TURBT, the first cystoscopy (a scope exam of the bladder) is typically done at three months, and the schedule after that depends on the tumor’s risk profile.¹⁷ Low-risk tumors may move to yearly checks after a couple of clean scopes, while high-risk tumors often require cystoscopy every three months for the first two years, then every six months, and then annually, potentially for the rest of your life.

Cystoscopy is the gold standard for detecting recurrence, but it is invasive and uncomfortable, and patients understandably dread it. Researchers are actively developing urine-based tests that could reduce the need for repeated cystoscopies. Current urine cytology is good at detecting high-grade recurrences but often produces equivocal results for low-grade disease.¹⁸ Newer molecular assays are more sensitive, but none has yet proven reliable enough to fully replace the scope. For now, expect cystoscopy to remain the backbone of your follow-up plan.

Diet, Smoking, and Everyday Choices

Patients naturally want to know what they can do to lower their risk of the tumor coming back. Diet appears to play a role. A case-control study of late recurrence in non-muscle-invasive bladder cancer found several dietary factors independently linked to recurrence risk. Low intake of cruciferous vegetables (things like broccoli, cabbage, and cauliflower) was associated with roughly two and a half times the odds of recurrence. Drinking less than a liter of water a day and eating preserved seafood more than once a week were also associated with higher risk.¹⁹ These are observational findings, not proof of causation, but the consistent dose-response trends make the association worth paying attention to.

Smoking is the biggest known risk factor for developing bladder cancer in the first place, and quitting is universally recommended. The picture for recurrence after diagnosis, however, is muddier than you might expect. One study found that smoking status, smoking intensity, and even having quit before diagnosis did not significantly alter recurrence or progression risk in patients with non-muscle-invasive disease.²⁰ That does not mean smoking is harmless after a diagnosis. It increases anesthesia risks for future procedures, impairs wound healing, and raises the risk of other cancers and cardiovascular disease. But the specific claim that quitting will prevent your bladder tumor from recurring is not well supported by the current evidence.

Staying well-hydrated is a practical step that may help for multiple reasons. Higher fluid intake dilutes potential carcinogens in the urine and shortens the time they spend in contact with the bladder lining. Pelvic floor exercises can also be useful in the recovery period, particularly for patients experiencing urinary incontinence or urgency after surgery. A systematic review found that Kegel exercises significantly reduced urinary incontinence in patients recovering from urologic surgery.²¹

Sexual Function After Treatment

Sexual side effects are one of the least-discussed aspects of bladder cancer treatment, despite being common and distressing. Even a TURBT, which preserves the bladder, can temporarily affect sexual function through anxiety, pain, and the emotional weight of a cancer diagnosis. A narrative review of male sexual function after urologic cancers found that even tumors not directly involving the genitals, including bladder and kidney cancers, affected sexual function. Changes in body image, anxiety, depression, and fear of recurrence all contributed to sexual difficulties regardless of where the cancer was located.²²

For patients who undergo radical cystectomy, the impact on sexual function is more direct. In men, the prostate and seminal vesicles are typically removed along with the bladder, which affects erections and eliminates ejaculation. Nerve-sparing surgical techniques can preserve erectile function in some cases. In women, radical cystectomy traditionally involved removal of the uterus, ovaries, and part of the vaginal wall, which profoundly affected sexual sensation and intercourse. Newer nerve-sparing approaches that preserve the urethra and vaginal tissue have shown significantly better sexual outcomes.²³ If cystectomy is on the table, asking your surgeon about nerve-sparing options and their experience with these techniques is worth doing before the operation, not after.

The Financial Reality

Bladder cancer is, per patient, the most expensive malignancy to manage.²⁴ The main driver is the long surveillance timeline. Years of cystoscopies, imaging, intravesical treatments, and potential additional surgeries add up. For high-risk patients whose disease progresses after BCG, costs can exceed $200,000 over five years when inpatient, outpatient, and physician expenses are combined.²⁵

Financial toxicity is the term researchers use for the way treatment costs degrade quality of life, and it is a recognized problem in bladder cancer care. Rising treatment costs and the potential for prolonged therapy mean this is something worth planning for early. Ask your care team about financial counseling services, understand what your insurance does and does not cover for long-term surveillance, and look into patient assistance programs if intravesical therapies are prescribed. The medical side of bladder cancer gets most of the attention, but the financial side can be just as draining if you are caught off guard.